Trials / Recruiting
RecruitingNCT05395689
Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM
Efficacy and Safety Assessment of a Subcutaneous Immunotherapy (Beltavac®) With Polymerized Allergenic Extract From House Dust Mites in Patients With Allergic Rhinitis/Rhinoconjuntivitis
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 350 (estimated)
- Sponsor
- Probelte Pharma S.L.U. · Industry
- Sex
- All
- Age
- 12 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The trial is performed to assess efficacy and safety of Beltavac with polymerized extract of house dust mites in allergic Rhinoconjunctivitis associated or not with asthma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae | The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year |
| BIOLOGICAL | Placebo | The vaccine will be administered according to a rush schedule meaning one administration each month for 1 year |
Timeline
- Start date
- 2022-01-17
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2022-05-27
- Last updated
- 2024-07-18
Locations
18 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT05395689. Inclusion in this directory is not an endorsement.